Table 5.
Model A seroprevalence in humans: Estimates of LB incidence, prevalence and total infections for 2018. Mean seroprevalence for multiple studies in one country.
| Country | Number of Studies | Region/Area | Sero-positives (SP) | True positives (Linear growth to 2018) | LB Incidence | LB Prevalence | Borrelia Infections |
|---|---|---|---|---|---|---|---|
| Austria | 1 | Tyrol/Rural | 7.2% | 9.1% | 37,430 | 189,185 | 798,059 |
| Belgium | 2 | National/Urban + Rural | 3.7% | 2.9% | 15,691 | 79,311 | 334,566 |
| England | 1 | Northwest/Rural | 2.7% | 2.1% | 54,005 | 272,964 | 1,151,474 |
| Finland | 1 | Southwest/Urban | 4.0% | 4.1% | 10,648 | 53,821 | 227,038 |
| France | 2 | See Table A1 | 9.6% | 13.9% | 438,962 | 2,218,688 | 9,359,322 |
| Germany | 5 | See Table A1 | 6.4% | 11.8% | 456,187 | 2,305,752 | 9,726,595 |
| Ireland | 2 | See Table A1 | 6.6% | 8.6% | 19,384 | 97,975 | 413,296 |
| Italy | 1 | Tuscany/Urban + Rural | 4.9% | 5.3% | 146,497 | 740,454 | 3,123,537 |
| Lithuania | 1 | National/Urban | 4.0% | 4.3% | 5806 | 29,344 | 123,787 |
| Netherlands | 3 | See Table A1 | 6.8% | 9.0% | 72,454 | 366,213 | 1,544,836 |
| Poland | 2 | See Table A1 | 9.6% | 13.3% | 106,225 | 536,901 | 2,264,865 |
| Scotland | 1 | National/Urban + Rural | 4.2% | 3.8% | 9463 | 47,832 | 201,774 |
| Sweden | 9 | See Table A1 | 8.7% | 12.3% | 57,556 | 290,911 | 1,227,178 |
| Switzerland | 1 | Alpine/Urban + Rural | 6.0% | 7.9% | 31,310 | 158,251 | 667,567 |
| Turkey | 2 | See Table A1 | 5.1% | 5.1% | 197,050 | 995,969 | 4,201,401 |
| Mean | 5.5% | 6.7% |